中國Court CasesCourtsEIP Coffee BreakEIP Patent 101 CornerprosecutionSupreme People's Court
2021年8月19日

Do Invention and UM Patents Filed on the Same Day Rise and Fall Together?

Snippets of Court Cases, Provisions, and Key Observations about China’s IP Landscape

Seminal Cases by the SPC

Recently, the Intellectual Property Division of the Supreme People's Court (SPC) issued a list of seminal (精品) cases. Although China is not a case law country, such seminal cases issued by the SPC have high guiding impact for similar cases in the future, so they are still worthy of attention.

One of the seminal cases ((2020) 最高法知民终699号) is very interesting. It involves a set of “same day applications”, i.e. an invention patent and utility model (UM) patent directed towards the same invention filed on the same day. The key issue is: if the invention patent application is rejected, what happens to the corresponding granted UM?

A Bit of Background

China allows patent applicants to apply for Invention and UM patents for the same invention on the same day (same-day applications). Typically the UM grants first (within 5-8 months), allowing the patentee to initiate license agreements or enforcement actions based thereon. Then later, when (and if) the time-consuming and costly invention application finally proceeds to grant, the applicant can obtain an invention patent’s longer 20-year protection term by giving up the UM patent (10 year term). Applicants welcome this dual application strategy, since it provides fast and comprehensive protection for product inventions.

Same Day Applications

In this seminal case, the applicant had obtained a granted UM earlier, but the corresponding invention patent application had been finally rejected, even after a re-examination request and administrative suit. Later the patentee initiated an infringement lawsuit based on the same-day UM patent which protects an identical technical solution. The first instance held in favor of the patentee. The SPC revoked the judgment of the first instance and held that in this case, the patent right for the utility model should be questioned.

Generally speaking, if a same-day invention application is rejected for lacking novelty, then the related same-day UM patent must also lack novelty, and thus will not meet the grant requirements. However, if the invention application is rejected for lack of inventiveness, then the judge cannot directly arrive at the same conclusion, since inventiveness requirements for invention patents and UMs are different.

We believe that this judgment is reasonable and will effectively reduce litigation costs in similar situations. We are of view that this judgment will not have significant impact on the same-day filing strategy for high-quality inventions.

You may refer to our previous article regarding same-day filing strategy.

(http://ipc.court.gov.cn/m/detail.html?id=1410)

About the Authors

Yolanda Wang is a Principal, Chinese Patent Attorney, and Chinese Patent Litigator at Eagle IP, a Boutique Patent Firm with offices in Hong Kong, Shenzhen, and Macau.

Jennifer Che, J.D. is Vice President and Principal at Eagle IP, a Boutique Patent Firm with offices in Hong Kong, Shenzhen, and Macau.

This article is for general informational purposes only and should not be considered legal advice or a legal opinion on a specific set of facts.

其他文章

Please “Mind the Traps”: Four Common Misconceptions About Hong Kong Patents

2026年4月13日
For many foreign companies interested in the broader Asian market, Hong Kong is a strategically important jurisdiction. However, because of its unique legal framework, domestic and foreign companies alike are confused by how IP protection works in Hong Kong. Missteps in such understanding can lead to critical, costly "gaps" in IP protection. To safeguard innovations […]

CNIPA Releases Interim Measures for the Amended Chinese Patent Law Going Into Effect June 1, 2021

2021年5月28日
Breaking News! We finally have more details about the new Chinese Patent Law which will go into effect on June 1, 2021. The full set of measure can be found at this link. Below are some pertinent points. No Implementation Rules . . . . Yet The new Implementation Rules will not be available by […]

No % homology? How to craft allowable claim scope around sequences to comply with China’s strict written description requirements

2018年11月23日
Since 2010, the Patent Re-examination Board (PRB) has published the top 10 patent invalidation cases of the year in April of each year. The selection criteria are high social concern, significant impact on the related industry, or involve difficult legal issues and important examination criteria. Below is one of the top 10 cases that discusses […]

Beijing IP Court Reverses CNIPA Decision and Upholds Ozempic® semaglutide patent in China as VALID based on Novo Nordisk’s Post Filing Data

2024年6月27日
Recently, all eyes have been on China as the fundamental patent covering semaglutide, the active ingredient in Ozempic® and Wegovy®, will expire on March 20, 2026. It goes without saying that generics are ramping up bigtime in China (and also around the world), preparing to manufacture and sell this blockbuster drug to one of the […]

我們過去活動

Top crossarrow-right